Soleno Therapeutics, Inc. (SLNO) has been on a downward spiral lately with significant selling pressure. After declining 21.7 ...

Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face ...

H.C. Wainwright raised the firm’s price target on Soleno Therapeutics (SLNO) to $110 from $100 and keeps a Buy rating on the shares. The firm says ...

Soleno Therapeutics Inc (NASDAQ:SLNO) stock fell 13% Friday morning following a short report from Scorpion Capital that raised serious concerns about the company’s recently approved Prader-Willi ...

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Soleno Therapeutics Inc (Symbol: SLNO), where a total volume of 2,502 ...

Opportunity, LLC Vivo, a 10% owner of $SLNO, sold 1,100,000 shares of the company on 03-27-2025 for an estimated $74,580,000. We received data on the trade from a recent SEC filing.

Scorpion Capital disclosed a short position in Soleno Therapeutics on Friday, citing issues with the drugmaker's recently approved treatment Vykat XR, sending its shares slumping 15% in premarket ...

Soleno Therapeutics (SLNO) is scheduled to report earnings on March 5, 2025. The last reported earnings were for reported on November 6, 2024 for Q3. Q ...

Soleno Therapeutics Inc. (NASDAQ:SLNO) Soleno Therapeutics soared by 46.6 percent week-on-week to end at $71.99 on Friday versus the $49.11 close on March 21, after securing the approval of the ...

Soleno Therapeutics Inc. (NASDAQ:SLNO) Soleno Therapeutics jumped for a second day on Friday, adding another 6.83 percent to its valuation to end at $71.99 apiece after securing the approval of ...